GNL Gut and Liver
  1. Xavier Roblin, Robert D. Little, Nicolas Mathieu, Stephane Paul, Stephane Nancey, Mathide Barrau, Miles P. Sparrow. Therapeutic drug monitoring in inflammatory bowel disease: recent developments. Expert Review of Gastroenterology & Hepatology 2024;18:575
    https://doi.org/10.1080/17474124.2024.2409300
  2. Hiroshi Nakase, Motohiro Esaki, Fumihito Hirai, Taku Kobayashi, Katsuyoshi Matsuoka, Minoru Matsuura, Makoto Naganuma, Masayuki Saruta, Kiichiro Tsuchiya, Motoi Uchino, Kenji Watanabe, Tadakazu Hisamatsu, Akira Andoh, Shigeki Bamba, Motohiro Esaki, Mikihiro Fujiya, Kitaro Futami, Keisuke Hata, Fumihito Hirai, Sakiko Hiraoka, Tadakazu Hisamatsu, Ryota Hokari, Shunji Ishihara, Soichiro Ishihara, Michio Itabashi, Yoichi Kakuta, Jun Kato, Shingo Kato, Takehiko Katsurada, Kazuya Kitamura, Kiyonori Kobayashi, Taku Kobayashi, Kazutaka Koganei, Atsuo Maemoto, Toshiyuki Matsui, Takayuki Matsumoto, Katsuyoshi Matsuoka, Minoru Matsuura, Satoshi Motoya, Masakazu Nagahori, Makoto Naganuma, Yuji Naito, Shiro Nakamura, Hiroshi Nakase, Haruhiko Ogata, Kazuichi Okazaki, Hirotake Sakuraba, Masayuki Saruta, Shinichiro Shinzaki, Ken Sugimoto, Akira Sugita, Yasuo Suzuki, Kenichi Takahashi, Tomohisa Takagi, Kento Takenaka, Ken Takeuchi, Kiichiro Tsuchiya, Tomoyuki Tsujikawa, Motoi Uchino, Fumiaki Ueno, Kenji Watanabe, Mamoru Watanabe, Takayuki Yamamoto, Kaoru Yokoyama, Atsushi Yoshida, Naoki Yoshimura. Treatment escalation and de-escalation decisions in Crohn’s disease: Delphi consensus recommendations from Japan, 2021. J Gastroenterol 2023;58:313
    https://doi.org/10.1007/s00535-023-01958-z
  3. Isabel Pinto Pais, Maria C. Espinheira, Eunice Trindade, Jorge Amil Dias. Optimizing Antitumor Necrosis Factor Treatment in Pediatric Inflammatory Bowel Disease With Therapeutic Drug Monitoring. J. pediatr. gastroenterol. nutr. 2020;71:12
    https://doi.org/10.1097/MPG.0000000000002704
  4. Sara Salvador-Martín, Alejandra Melgarejo-Ortuño, Luis A. López-Fernández. Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease. Pharmaceutics 2021;13:1786
    https://doi.org/10.3390/pharmaceutics13111786
  5. Abigail Samuels, Kaitlin G. Whaley, Phillip Minar. Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease. Curr Gastroenterol Rep 2023;25:323
    https://doi.org/10.1007/s11894-023-00895-4
  6. Joshua M. Steinberg, Aline Charabaty. The Management Approach to the Adolescent IBD Patient: Health Maintenance and Medication Considerations. Curr Gastroenterol Rep 2020;22
    https://doi.org/10.1007/s11894-019-0739-9
  7. Amara Nassar-Sheikh Rashid, Dieneke Schonenberg-Meinema, Sophie E. Berends, J. Merlijn van den Berg, Ron A.A. Mathôt. Population Pharmacokinetics of Infliximab in Children with Juvenile Idiopathic Arthritis. 2022;44:301
    https://doi.org/10.1097/FTD.0000000000000914
  8. Hitoshi Tajiri, Katsuhiro Arai, Seiichi Kagimoto, Reiko Kunisaki, Nobuyuki Hida, Noriko Sato, Hiroshi Yamada, Mieko Nagano, Yutaka Susuta, Kunihiko Ozaki, Kazuoki Kondo, Toshifumi Hibi. Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan. BMC Pediatr 2019;19
    https://doi.org/10.1186/s12887-019-1739-5
  9. Logan Jerger, Jeffrey S. Hyams. Special considerations for biologic medications in pediatric ulcerative colitis. Expert Opinion on Biological Therapy 2020;20:429
    https://doi.org/10.1080/14712598.2020.1685492
  10. Soyoon Choi, Won Moon. Pediatric-onset Inflammatory Bowel Disease: What Are Different from Adult in the Treatment?. Korean J Gastroenterol 2021;77:220
    https://doi.org/10.4166/kjg.2021.067
  11. Laura Guberna, Olga P. Nyssen, María Chaparro, Javier P. Gisbert. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. JCM 2021;10:2132
    https://doi.org/10.3390/jcm10102132
  12. Eun Sil Kim, Yiyoung Kwon, Yon Ho Choe, Mi Jin Kim. Free antibodies-to-infliximab are biomarker for predicting the effect of dose intensification in pediatric Crohn’s disease patients with secondary loss of response. Therap Adv Gastroenterol 2023;16
    https://doi.org/10.1177/17562848231170948
  13. Chang Soo Eun. Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?. Gut and Liver 2017;11:3
    https://doi.org/10.5009/gnl16574
  14. Karen van Hoeve, Erwin Dreesen, Ilse Hoffman, Gert Van Assche, Marc Ferrante, Ann Gils, Séverine Vermeire. Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease. J. pediatr. gastroenterol. nutr. 2019;68:847
    https://doi.org/10.1097/MPG.0000000000002265
  15. Karen van Hoeve, Ilse Hoffman, Severine Vermeire. Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease. Expert Opinion on Drug Safety 2018;17:185
    https://doi.org/10.1080/14740338.2018.1413090
  16. Ju Young Kim, Yoon Lee, Byung-Ho Choe, Ben Kang. Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease. Gut and Liver 2021;15:588
    https://doi.org/10.5009/gnl20134
  17. Yiyoung Kwon, Ben Kang, Eun Sil Kim, Yon Ho Choe, Mi Jin Kim. Comparison of Ustekinumab Trough Concentrations Measured by 2 ELISA Kits and Evaluation of Clinical Response in Crohn’s Disease. 2022;44:535
    https://doi.org/10.1097/FTD.0000000000000976
  18. Qingqing Du, Yan Qian, Weiwei Xue. Molecular Simulation of Oncostatin M and Receptor (OSM–OSMR) Interaction as a Potential Therapeutic Target for Inflammatory Bowel Disease. Front. Mol. Biosci. 2020;7
    https://doi.org/10.3389/fmolb.2020.00029
  19. Akshay Kapoor, Eileen Crowley. Advances in Therapeutic Drug Monitoring in Biologic Therapies for Pediatric Inflammatory Bowel Disease. Front. Pediatr. 2021;9
    https://doi.org/10.3389/fped.2021.661536
  20. Ben Kang, So Yoon Choi, Young Ok Choi, Soo-Youn Lee, Sun-Young Baek, Insuk Sohn, Byung-Ho Choe, Hae Jeong Lee, Yon Ho Choe. Infliximab Trough Levels Are Associated With Mucosal Healing During Maintenance Treatment With Infliximab in Paediatric Crohn’s Disease. 2019;13:189
    https://doi.org/10.1093/ecco-jcc/jjy155
  21. Nicholas Carman, David R. Mack, Eric I. Benchimol. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. Curr Gastroenterol Rep 2018;20
    https://doi.org/10.1007/s11894-018-0623-z
  22. Dwight A. Winter, Maria E. Joosse, Saskia N. de Wildt, Jan Taminiau, Lissy de Ridder, Johanna C. Escher. Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Infliximab in Pediatric Inflammatory Bowel Disease. J. pediatr. gastroenterol. nutr. 2020;70:763
    https://doi.org/10.1097/MPG.0000000000002631
  23. Bella Ungar, Yoav Glidai, Miri Yavzori, Orit Picard, Ella Fudim, Avishay Lahad, Yael Haberman, Dror S. Shouval, Ilana Weintraub, Rami Eliakim, Shomron Ben‐Horin, Batia Weiss. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases. J. pediatr. gastroenterol. nutr. 2018;67:507
    https://doi.org/10.1097/MPG.0000000000002051
  24. Karen van Hoeve, Erwin Dreesen, Ilse Hoffman, Gert Van Assche, Marc Ferrante, Ann Gils, Séverine Vermeire. Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease. 2018;12:1316
    https://doi.org/10.1093/ecco-jcc/jjy111
  25. Hitoshi Tajiri, Satoshi Motoya, Fukunori Kinjo, Atsuo Maemoto, Takayuki Matsumoto, Noriko Sato, Hiroshi Yamada, Mieko Nagano, Yutaka Susuta, Kunihiko Ozaki, Kazuoki Kondo, Toshifumi Hibi, Emiko Mizoguchi. Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan. PLoS ONE 2018;13:e0201956
    https://doi.org/10.1371/journal.pone.0201956
  26. Raffaella Franca, Debora Curci, Marianna Lucafò, Giuliana Decorti, Gabriele Stocco. Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease. Expert Opinion on Drug Metabolism & Toxicology 2019;15:527
    https://doi.org/10.1080/17425255.2019.1630378
  27. Yon Ho Choe. Precision medicine for pediatric inflammatory bowel disease: a perspective. Precis Future Med 2020;4:43
    https://doi.org/10.23838/pfm.2020.00058
  28. Dwight A. Winter, Pauline de Bruyne, Janneke van der Woude, Dimitris Rizopoulos, Lissy de Ridder, Janneke Samsom, Johanna C. Escher. Biomarkers predicting the effect of anti‐TNF treatment in paediatric and adult inflammatory bowel disease. J. pediatr. gastroenterol. nutr. 2024;79:62
    https://doi.org/10.1002/jpn3.12221
© 2023. Gut and Liver. / Powered by INFOrang Co., Ltd